Chardan Capital maintains Buy rating on ProQR Therapeutics, $3 price target
Chardan Capital maintained a Buy rating on ProQR Therapeutics (PRQR) with a $3.00 price target, implying 80.7% upside from the Sep 30 close of $1.66. The firm cited the company's strong clinical pipeline, including AX-0811, and expert validation of its therapies for genetic disorders.
How this was made
The 30-second read
Why it matters
Analyst maintains Buy rating and raises price target, suggesting upside potential.
Market read
New price target could attract short‑term buying in PRQR.
What to watch
No new clinical data released; the target relies on expectations.
Background
ProQR Therapeutics is a small‑cap biotech focused on RNA editing technologies.
Ticker impact
Chardan Capital maintained a Buy rating on ProQR Therapeutics and set a new $3 price target, implying 80.7% upside.
potential upward pressure as investors price in the new target
The fresh price target provides a concrete catalyst for short‑term buying.
Market effects
May lift sentiment in the RNA‑therapeutics niche.
Limited to U.S. biotech investors.
Low
Counterpoint
The price target may be overly optimistic given early‑stage pipeline risk.
Key entities
- companyProQR Therapeutics
RNA‑editing biotech (ticker PRQR).
- analystChardan Capital
Equity research firm issuing the rating.